Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma

被引:220
作者
Kumada, T [1 ]
Nakano, S [1 ]
Takeda, I [1 ]
Sugiyama, K [1 ]
Osada, T [1 ]
Kiriyama, S [1 ]
Sone, Y [1 ]
Toyoda, H [1 ]
Shimada, S [1 ]
Takahashi, M [1 ]
Sassa, T [1 ]
机构
[1] OGAKI MUNICIPAL HOSP, DEPT PATHOL, OGAKI, GIFU 503, JAPAN
关键词
D O I
10.1002/hep.510250116
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
To assess intrahepatic metastasis (IM) and multicentric occurrence (MO) after initial treatment of small hepatocellular carcinomas (HCC) less than or equal to 2 cm in diameter, we performed clinical and pathological studies in 112 patients who underwent percutaneous ethanol injection therapy (PEIT) or hepatic resection for HCC from January 1985 to December 1994, Patients with intrahepatic recurrences were classified into two groups based on the type of recurrence: the IM group (n = 29, 50.9%) and the MO group (n = 28, 49.1%), Overall recurrence rates after initial treatment were 23.7% at 1 year, 64.5% at 3 years, and 76.1% at 5 years, in patients with IM, the majority of intrahepatic recurrences were observed within 3 years of initial treatment and the primary HCC lesions were closely related to the degree of tumor cell differentiation, Alternatively, intrahepatic recurrences occurred throughout the follow-up period in patients with MO, and the evidence of underlying liver disease (anti-HCV [antibody to hepatitis C virus] positive) and elevated serum alfa-fetoprotein (AFP) concentrations were closely associated with intrahepatic recurrence, Prognoses following additional treatment in MO group patients were superior to those in IM group patients, These results suggest that differentiation between IM and MO in patients with HCC is important for understanding the development and biological behavior of the tumor, That is, the early detection of intrahepatic recurrence and the institution of appropriate additional therapy (PEIT or hepatic resection) may prolong survival in patients with MO.
引用
收藏
页码:87 / 92
页数:6
相关论文
共 38 条
[1]   RISK-FACTORS FOR INTRAHEPATIC RECURRENCE IN HUMAN SMALL HEPATOCELLULAR-CARCINOMA [J].
ADACHI, E ;
MAEDA, T ;
MATSUMATA, T ;
SHIRABE, K ;
KINUKAWA, N ;
SUGIMACHI, K ;
TSUNEYOSHI, M .
GASTROENTEROLOGY, 1995, 108 (03) :768-775
[2]  
CASTELLS A, 1993, HEPATOLOGY, V18, P1121
[3]   CLONAL ORIGIN OF RECURRENT HEPATOCELLULAR CARCINOMAS [J].
CHEN, PJ ;
CHEN, DS ;
LAI, MY ;
CHANG, MH ;
HUANG, GT ;
YANG, PM ;
SHEU, JC ;
LEE, SC ;
HSU, HC ;
SUNG, JL .
GASTROENTEROLOGY, 1989, 96 (02) :527-529
[4]  
Child CG., 1964, SURG PORTAL HYPERTEN
[5]  
COX DR, 1972, J R STAT SOC B, V34, P187
[6]   PERCUTANEOUS ETHANOL INJECTION FOR THE TREATMENT OF SMALL HEPATOCELLULAR-CARCINOMA - STUDY OF 95 PATIENTS [J].
EBARA, M ;
OHTO, M ;
SUGIURA, N ;
KITA, K ;
YOSHIKAWA, M ;
OKUDA, K ;
KONDO, F ;
KONDO, Y .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1990, 5 (06) :616-626
[7]  
EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO
[8]  
2-E
[9]   ADENOMATOUS HYPERPLASIA IN THE VICINITY OF SMALL HEPATOCELLULAR-CARCINOMA [J].
EGUCHI, A ;
NAKASHIMA, O ;
OKUDAIRA, S ;
SUGIHARA, S ;
KOJIRO, M .
HEPATOLOGY, 1992, 15 (05) :843-848
[10]  
HSU HC, 1991, HEPATOLOGY, V13, P923, DOI 10.1002/hep.1840130520